Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Risk categories predict mRCC survival

Rini B et al. Clin Genitourin Cancer. 2018 May 3. doi: 10.1016/j.clgc.2018.04.005.

Key clinical point: The IMDC model is prognostic for responses and survival in patients with mRCC treated with sunitinib.

Major finding: Median progression-free survival for favorable, intermediate, and poor-risk patients was 14.1, 10.7, and 2.4 months, respectively.

Study details: Retrospective analysis of 375 sunitinib-treated patients in a randomized clinical trial.

Disclosures: Medical writing for the study was supported by Pfizer. Dr. Rini and his coauthors disclosed research funding and/or consulting fees from Pfizer and other companies. Four of the coauthors are Pfizer employees and stockholders.

Source: Rini B et al. Clin Genitourin Cancer. 2018 May 3. doi: 10.1016/j.clgc.2018.04.005.

Read the article.

Citation:

Rini B et al. Clin Genitourin Cancer. 2018 May 3. doi: 10.1016/j.clgc.2018.04.005.